CNST Constellation Pharmaceuticals Inc.

+0.26  (+3%)
Previous Close 9.83
Open 9.85
Price To Book 3.02
Market Cap 260,394,941
Shares 25,807,229
Volume 663
Short Ratio
Av. Daily Volume 75,067

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 additional data due 4Q 2019.
CPI-0610 and ruxolitinib
Phase 2 trial initiated.
CPI-1205 ORIOn-E
Solid tumors
Phase 2 interim data due 2H 2019.
CPI-1205 - ProSTAR
Castration-resistant prostate cancer

Latest News

  1. Constellation Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
  2. Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209
  3. Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients
  4. Constellation Pharmaceuticals to Present at Jefferies Healthcare Conference
  5. Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial
  6. Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting
  7. Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts
  8. Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results
  9. Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
  10. Jim Cramer: What Dirty Lemon Tells Us About Market Tops and Millennials
  11. Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results
  12. Constellation Pharmaceuticals to Present at Upcoming Investor Conference
  13. Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development Officer
  14. What's in Store for Universal Health (UHS) Q4 Earnings?
  15. Constellation Pharmaceuticals to Present at Upcoming Investor Conferences
  16. Constellation Pharmaceuticals Announces Appointment to Board of Directors
  17. Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates
  18. Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y
  19. MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y
  20. Can Higher Revenues Buoy T-Mobile's (TMUS) Q4 Earnings?